News Briefing channel feed – Endpoints News

News Briefing channel feed

Intas to pay €42M upfront in Henlius deal; Kymera gets $40M milestone; Pluvicto no longer in short supply

Last year

Excision’s HIV gene editing clinical trial; Nykode’s $45M placement; Ideaya’s post-ESMO offering

Last year

BrainStorm to lay off workers; Lilly inks a subcutaneous deal

Last year

Harpoon, Aligos announce PIPEs; NAYA's all-stock deal; Invea to go public

Last year

Keytruda's cervical cancer data; Arcutis’ offering; Alaya.bio announces a CAR-T deal

Last year

Chan Zuckerberg’s new center in New York; Endeavor buys rights to ADC; Basilea acquires antifungal

Last year

Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M

Last year

Lumen gets $16M for C. diff drug; Flashpoint’s seed round; Amplifier expands Series A

Last year

Nuvalent’s $300M offering; Spark ends epilepsy deal; A small IPO

Last year

Harmony Biosciences' Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizes

Last year

FDA lifts hold on PepGen's myotonic dystrophy drug; Takeda teams with cancer nonprofit

Last year

Microbiome startup sells off assets; Faron's PhI/II data in bone marrow cancer; AM Pharma touts biomarker results

Last year

CEPI puts $25M into Rift Valley fever vaccine; Gates invests in AI for scientists in Africa in equity bid

Last year

BridgeBio’s long-term limb-girdle muscular dystrophy data; QHP buys a CDMO

Last year

Regeneron pays $100M milestone to Alnylam; NIH awards Clene $45M; Biohaven raises $258M

Last year

Bayer’s projects with Twist, Evotec; AbbVie buys out Parkinson’s drugmaker; A new drug discovery nonprofit in Toronto

Last year

Freeline’s early Gaucher disease data; Shorla raises $35M; Regenxbio to start pivotal DMD trial next year

Last year

Regeneron expands CRISPR deal with Intellia; Capsida, Kate's gene therapy manufacturing deal; Biohaven’s $225M offering

Last year

Rocket’s gene therapy gets a PDUFA date; SAB Biotherapeutics’ $130M; Acurx to move to PhIII

Last year

Merck KGaA's expanded AI deal; Ascletis has new biomarker data for its PD-L1; Deka closes $20M round

Last year

Immunovant's $450M; Oncopeptides reassesses Pepaxti strategy in Europe; Akebia resubmits kidney drug

Last year

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

Last year

Pakistan recalls altered dose of Avastin; FDA rejects Botanix gel

Last year

Antios reportedly shut down; Clene's long-term ALS data; Keytruda, Lenvima's lung cancer failures

Last year

First page Previous page 13 14 151617 18 19 Next page Last page